Azienda Sanitaria Locale To3

At Azienda Sanitaria Locale To3 in Rivoli, most of the clinical research focuses on cardiovascular diseases, with studies spanning heart attack care, stroke prevention, and long-term risk reduction. The trials are designed to test new treatments, compare treatment strategies, and improve outcomes for people with common and high-risk heart conditions.

• Acute coronary syndrome and myocardial infarction, including efforts to reduce inflammation and prevent major cardiovascular events
• Atrial fibrillation and stroke prevention, with research on safer ways to manage clotting risk
• Atherosclerotic cardiovascular disease, elevated lipoprotein(a), and broader prevention of heart, stroke, and vascular complications
• Heart failure and obesity-related cardiac disease, aiming to improve symptom control and reduce hospital visits

These studies reflect a strong interest in both immediate cardiac care and long-term prevention, including approaches that refine antiplatelet treatment, lower cholesterol-related risk, and evaluate therapies for patients with established cardiovascular disease or multiple risk factors.

The site also contributes to research in neoplasms, with clinical studies centered on breast cancer. This work is focused on evaluating new treatment combinations and comparing them with current standard therapies to help improve cancer control and patient outcomes.

• Metastatic HER2-positive breast cancer, with trials assessing whether newer targeted approaches can improve treatment effectiveness
• Combination therapy studies that compare cancer treatment strategies against established regimens

Although the oncology portfolio is smaller than the cardiovascular program, it shows active research into better treatment options for advanced breast cancer through studies of targeted and combination therapies.